Bracken fern is the environmental co-carcinogen of BPV-4 in the induction of neoplasias of the upper alimentary canal of cattle. The¯avonoid quercetin is one of the most potent and best characterised mutagens present in the fern. We have shown that transfection with BPV-4 DNA and exposure to a single dose of quercetin leads to tumorigenic transformation of primary bovine cells. We now show that quercetin induces cell cycle arrest and up-regulates transcription from the BPV-4 long control region (LCR). This up-regulation is mediated by a 21 nucleotide-long cis-element in the LCR, designated QRE-1, which is located immediately downstream of the TATA box. Cellular proteins bind to QRE-1 and removal or substitution of QRE-1 lead to the abrogation of the response to quercetin. As expression of the viral oncogenes is controlled by the LCR, perturbation in this control and increased oncoprotein expression are likely to contribute to fully malignant cell transformation by overcoming the cell cycle arrest induced by quercetin, thus forcing damaged cells to proliferate.
Introduction
Papillomaviruses are necessary, but often not sucient factors in the induction of squamous cell carcinomas of cutaneous and mucosal epithelia (Jackson et al., 1993) . Infection with virus results in the onset of benign lesions which can occasionally progress to cancer after a long period, during which it is believed that other carcinogenic events take place, often triggered by environmental cofactors. Bovine papilloma virus type 4 (BPV-4) infects the mucous epithelium of the upper alimentary canal of cattle and induces benign papillomas. These are rejected in the great majority of cases by a cell mediated immune response (Knowles et al., 1996) . However, cattle grazing on bracken fern are chronically immunosuppressed and incapable of mounting the appropriate rejection response, and as a consequence are subjected to life-long papillomatosis. The persistent papillomas are at high risk of neoplastic progression as they are continuously exposed to the mutagens present in the fern (Campo et al., 1994) . The¯a vonoid quercetin is perhaps the best characterised of the fern mutagents. It has been shown that quercetin induces mutations in both prokaryotic and eukaryotic cells (Bjieldanes and Chang, 1977; Nakayasu et al., 1986) , through the generation of DNA single-strand breaks (Rahaman et al., 1990; Fazal et al., 1990) and that it can substitute for DMBA in a two-stage cell transformation model (Sakai et al., 1990) . In addition to its mutagenic properties, quercetin induces cell cycle arrest (Hosokawa et al., 1990; Ranelletti et al., 1992; Plaumann et al., 1996) , disrupts normal cellular signalling pathways by interfering with kinases and phosphatases (Graziani et al., 1983; Van Wart-Hood et al., 1989; Matter et al., 1992) and induces protein degradation (Ahmed et al., 1994) .
BPV-4 transformed cells are not contact inhibited, can grow in low serum and in suspension (V O'Brien et al., in preparation; Pennie et al., 1993) but are not immortal or tumorigenic in nude mice (Jaggar et al., 1990; Pennie et al., 1993) . Exposure of BPV-4 transformed cells to a single dose of quercetin results in immortalisation and oncogenic progression (Pennie and Campo, 1992; Cairney and Campo, 1995) , strengthening the hypothesis that quercetin is one of the co-carcinogens in vivo. The synergism between BPV-4 and quercetin is dependent on the timing of exposure to the¯avonoid suggesting that the quercetin eect is partly epigenetic (Cairney and Campo, 1995) .
To elucidate the mechanisms underpinning the virusavonoid interaction, we have analysed the cell cycle progression of quercetin treated cells and the transcriptional activity of the LCR in the presence of quercetin. We show that quercetin induces cell cycle arrest in both G1 and G2 and that it induces a modest but noticeable and reproducible up-regulation of the LCR, in the same conditions in which it promotes malignant transformation. These two events are likely to play a role in the observed synergism: even a small increase in the expression of the viral oncogenes results in a greater degree of cell transformation (Smith et al., 1987; Jaggar et al., 1990) , and increased viral oncoprotein expression could force quercetin-arrested cells to proliferate, thus any genetic damage induced by the¯avonoid would be inherited by progeny cells.
Results

Quercetin inhibits cell growth and de-regulates cell cycle
Optimal synergism between quercetin and BPV-4 in the transformation of PalF cells was achieved at 25 mM quercetin (Pennie and Campo, 1992) . To investigate the eect of quercetin on cell growth and how this may bear on the observed transformed phenotype, we assessed the growth rate of PalF cells in the presence of quercetin. Control PalF cells, cells treated with 1 mM quercetin or ethanol showed the same growth rate, doubling approximately every 36 h. Cells treated with 20 mM quercetin had a noticeably increased doubling time and cell growth was almost totally inhibited at 50 mM or 100 mM quercetin (Figure 1a ). Clearly the degree of growth inhibition is proportional to quercetin concentration.
Growth inhibition can be due to cell death balancing cell proliferation, or to growth arrest at speci®c or random stages in the cell cycle. To address this point, cell cycle analysis was performed on cells treated with varying concentrations of quercetin (Figures 1b and c) . After 12 h of treatment, when the cells were exposed to 50 mM or 100 mM quercetin, there was a noticeable increase in cells in S phase (38 ± 41% of cells) paralleled by a decrease in the percentage of cells in G1 or G2. Cells treated with 20 mM, 50 mM or 100 mM quercetin accumulated in G1 after 24 h, and in G2 from 36 h onward when there was a parallel decrease of cells in G1 and S (Figures 1b and c) . Thus we conclude that after an initial accumulation of cells in S phase, quercetin induces growth arrest of PalF cells both in G1 and in G2.
Quercetin up-regulates the viral long control region
Exposure of PalF cells to 25 mM quercetin shortly after transfection of the cells with BPV-4 DNA results in full tumorigenic transformation. As it is known that even a moderate increase in the expression of the viral oncogenes leads to enhanced cell transformation (Jaggar et al, 1990) , we tested whether quercetin can upregulate the transcriptional activity of the viral long control region (LCR). The full length LCR (nt 6710-331; Figure 2 ) was cloned into the luciferase reporter vector pGL3 and its ability to drive expression of the luciferase gene was examined in PalF cells treated with quercetin or with its solvent ethanol. Quercetin was used at 20 mM concentration and was administered after DNA transfection, in the same conditions that give rise to tumorigenically transformed cells. In quercetin-treated PalF cells the transcriptional activity of the BPV-4 LCR was consistently increased between 2 ± 5-fold (P=0.002) (Figure 3a) . Quercetin up-regulation of the LCR was much decreased in low serum (P=0.05) (Figure 3a) , suggesting that up-regulation is dependent on growth factor signalling.
TPA does not up-regulate the viral LCR
An examination of the nucleotide sequence of the LCR revealed a motif TGAGGCA (nt 313 ± 319), 22 nucleotides downstream of the early promoter TATA box, which is only one nucleotide dierent from the consensus TPA-responsive element (TRE) sequence TGAGTCA (Angel et al., 1987) . To investigate whether this element responds to TPA and mediates the up-regulation by quercetin, the transcriptional a b activity of the LCR was monitored after treatment of PalF cells with TPA and/or quercetin. TPA treatment (100 ng ml) did not up-regulate the LCR, either in high or in low serum (Figure 3a ), whereas the collagenase promoter which contains a bona ®de TRE (Witham et al., 1986) was up-regulated approximately three times in low serum ( Figure 3b ). Quercetin had no eect on the collagenase promoter, either in high or low serum (Figure 3b) . Surprisingly, TPA abrogated quercetin upregulation of the LCR (Figure 3a) , and quercetin abrogated TPA up-regulation of the collagenase promoter ( Figure 3b ). These results suggest that the signalling pathways of quercetin and TPA are antagonistic.
A 21 nucleotide sequence downstream of the TATA box mediates up-regulation by quercetin
Although the BPV-4 LCR did not respond to TPA, we decided to investigate whether the LCR region comprising the TRE-like element was responsible for the observed up-regulation by quercetin. A deletion mutant of the LCR was constructed, which lacks 21 nucleotides at its 3' terminus (nt 311 ± 331) including the TRE-like motif. This deleted version of the LCR is de®ned sLRC (Figure 2 ). The sLCR showed a slightly decreased basal transcription activity and quercetin treatment failed to up-regulate it (P=0.11; Figure 4 ). A random oligonucleotide was used to replace the 21 nucleotide sequence deleted from full length LCR ( Figure 2 ) to rule out that the eect observed with sLCR was due to mere physical rearrangement of the sequences. The random oligonucleotide was chosen so that both the TRE-like element and the stretch of pyrimidines (see below) were mostly destroyed. The resulting rLCR was not up-regulated by quercetin (P=0.23; Figure 4 ). These results indicate that the 21 nucleotide sequence, hereon designated QRE-1, contributes to the up-regulation of LCR activity induced by quercetin treatment.
A series of 5' deletion mutants of the LCR (Jackson and Campo, 1991; Morgan IM et al, in preparation) was tested for response to quercetin. There were no signi®cant dierences in the mutants' response to quercetin (data not shown; Connolly, 1997) , confirming that QRE-1 is the major mediator of quercetin upregulation of the LCR.
QRE-1 binds cellular protein(s)
A 25 bp-long QRE synthetic oligonucleotide was used in electrophoretic mobility shift assays (EMSA) to analyse its interactions with PalF nuclear proteins. The oligonucleotide formed several complexes with cellular proteins ( Figure 5a , lane 2), the most prominent of which will be the only one discussed here; the other bands were either clearly non speci®c complexes or were not consistently observed. The complex had a 5); the AP1-TRE complex could be only partially competed by excess QRE oligonucleotide (lane 9). These reuslts show that QRE speci®cally binds a cellular factor, designated QX, distinct from AP1.
QX is not AP1
Antibodies against c-Jun, JunB and JunD and a pan antibody against Fos proteins were used in supershift experiments to con®rm the distinct nature of QX and AP1. The anti-cJun antibody did supershift the AP1-TRE complex while the anti-Fos antibody destroyed the complex (Figure 5b, lanes 3 and 4) . Neither antibody aected the QX-QRE complex (Figure 5b , lanes 8 and 9). The band at the top of the gel in lane 8 was observed also with pre-immune serum (lane 10) Figure 2 Schematic representation of the BPV-4 LCR. The E2 binding sites are shown (Jackson and Campo, 1991) , as are the C/ EBPb binding site (McCaery and Jackson, 1994) , the PEBP2 binding site (Jackson and Campo, 1995) , the PEF1 binding site (Cuthill et al., 1993) and the putative NF1 binding sites. The TRE-like and INR-like elements are shown downstream of the TATA box and the sequence of this region is expanded below, where the consensus TRE is shown; the TRE-like element and the INR-like element are boxed and underlined respectively. sLCR terminates at nucleotide 310. The random 21-nucleotide sequence present in rLCR is shown beneath nucleotide 311 ± 331 Figure 3 Trans-activation of the LCR by quercetin. (a) The basal activity of the LCR in ethanol, the solvent for quercetin, is normalised to 1, and the activity of the LCR in the presence of quercetin and/or TPA is reported as fold activation. (b) The basal activity of the collagenase promoter is normalised to 1, and its activity in the presence of TPA and/or quercetin is reported as fold activation. HS, high serum (10%); LS, low serum (0.5%). Standard Error of the Mean (s.e.m.) is indicated Figure 4 Basal activity and response to quercetin of full length LCR, short LCR and random LCR. The basal activity of full length LCR is normalised to 1, and the activities of the LCR mutants are reported as fold activation, as in Figure 3 , s.e.m. is indicated and is therefore non speci®c. Identical results were obtained with anti-JunB and anti-JunD antibodies (data not shown). These results con®rm that the QX-QRE complex is unlikely to contain AP1 components.
Mutation of QRE-1 to TRE results in AP1 binding
The sequence TGAGGCA in the QRE oligonucleotide was mutated to the consensus TRE sequence TGAGTCA and the mutant oligonucleotide was used in EMSA with PalF nuclear protein extracts. The mutant oligonucleotide formed complexes with both AP1 and QX ( Figure 6 , lane 5), again con®rming that QX is distinct from AP1. No complex containing both AP1 and QX was observed suggesting that binding of the two factors is mutually exclusive. The increased binding of QX by the mutant oligonucleotide may be due to the introduced mutation itself, but this was not investigated further.
Discussion
We have previously demonstrated that BPV-4 and quercetin synergise powerfully in the transformation of primary cells to tumorigenicity (Pennie and Campo, 1992; Cairney and Campo, 1995) . To understand the mode of action of the¯avonoid and the mechanisms underpinning the virus ± chemical synergism, we investigated two potential outcomes of exposure to quercetin: the cell response to quercetin treatment and the transcriptional activity of the viral LCR promoter in the presence of quercetin.
Quercetin inhibits proliferation of PalF cells
Quercetin has dierent eects in dierent cell or animal systems. Thus it behaves as an initiator in a two stage in vitro cell transformation model (Sakai et al., 1990) and potentiates the carcinogenic activity of azoxymethane in rats (Pereira et al., 1996) , but it inhibits the action of TPA in mice (Kato et al., 1983) and causes cell growth arrest in a variety of tumour or established cell types (Hosokawa et al., 1990; Ranelletti et al., 1992; Scambia et al., 1993; Piantelli et al., 1995; Avila et al., 1994; Plaumann et al., 1996) . Its cytostatic eect has prompted the proposal that quercetin be used as an anticancer agent . These previous studies on cell growth arrest were all conducted on transformed or established cells. Given a dierent outcome of quercetin exposure depending on cell type and culture conditions, we asked what eect quercetin would have on the growth of PalF cells. Indeed PalF cells do undergo growth arrest when exposed to quercetin concentrations (20 ± 100 mM) similar to those reported for established cells (60 ± 120 mM; Plauman et al., 1996) but considerably higher than for tumour cells (1 nM ± 1 mM; Scambia et al., 1993; Piantelli et al., 1995) , con®rming that the genetic background of the cell determines at least in part its response to thē avonoid. During the ®rst 12 h of quercetin treatment at higher doses (50 and 100 mM) almost twice as many PalF cells are in S phase than untreated cells. At later times, with the exception of cells exposed to the lowest dose of quercetin, quercetin treated cells arrest in G1 and in G2, in agreement with previous reports (Plaumann et al., 1996) . These results suggests a model in which PalF cells that have already travelled past the quercetin G1 block at the beginning of the treatment, can enter S phase and proceed through the cycle until they meet the second quercetin block in G2. Cells that have already passed the G2 block when exposed to quercetin, travel through M and subsequently stop in G1.
What would be the impact of quercetin-induced cell cycle de-regulation on papillomavirus cell transformation? Treatment with quercetin and transfection with BPV-4 oncogenes have to be close to each other for synergism to take place (Cairney and Campo, 1995) , suggesting that viral products act on cells temporarilỳ primed' by quercetin. Any increase in LCR transcriptional activity, and therefore in viral oncoprotein expression, would further contribute to cell transformation, as reported for other papillomaviruses (Von Knebel Doeberitz et al., 1994; Trujillo and Mounts, 1996) .
Quercetin up-regulates transcription from the viral LCR
We analysed the transcriptional activity of the BPV-4 LCR in quercetin-treated cells in the same culture conditions which promote maximum cell transformation (Cairney and Campo, 1995) , and found that LCR activity was consistently increased between two ± ®ve-fold. Thus, up-regulation of the BPV-4 LCR by quercetin could make a substantial contribution to cell transformation.
Increased LCR activity in the presence of quercetin is observed only in high serum suggesting that growth factor signalling is necessary for quercetin action. The elucidation of the pathway used by quercetin to stimulate the transcription activity of the LCR requires further study.
QRE-1 mediates quercetin up-regulation
The quercetin-induced up-regulation of the viral LCR is mediated by a 21 bp segment, designated QRE-1, at the 3' end of the LCR, downstream of the TATA box, and the removal or substitution of this segment leads to the abrogation of trans-activation. QRE-1 includes a 7 bp motif which diers from a consensus TRE by only one nucleotide. Despite the extensive homology between TRE and the 7 bp motif of QRE, quercetin up-regulation is not mediated by AP1 and QRE binds cellular proteins, but does not complex with AP1. This conclusion is supported by numerous observations. TPA treatment fails to stimulate the viral LCR even in low serum, and it actually inhibits quercetin upregulation of the LCR. The reciprocal inhibition by TPA and quercetin of the up-regulation of the respective target promoters is intriguing and suggests that the pathways used by the phorbol ester and thē avonoid are incompatible and antagonistic. Indeed it has been shown that while TPA activates protein kinase C (Nishizuka, 1984) , quercetin inhibits it (Gschwendt et al., 1984) .
QRE forms a complex with a cellular factor, QX-1, which exhibits a faster electrophoretic mobility than the TRE-AP1 complex and is not aected by antibodies against AP1 components, con®rming that canonical AP1 is not involved in interactions with QRE. No dierences were observed in complex formation by QRE in control or quercetin-treated Pa1F cells, and it is therefore not yet clear how quercetin activates the complex. Phosphorylation may be a way of regulating QX-1 activity, and it has been found that quercetin treatment induces changes in protein tyrosine phosphorylation (data not shown; Connolly, 1997) .
Mutation of the TRE-like element in QRE to consensus TRE leads to complex formation with both QX and AP1, but not with the two together, as shown by the absence of a complex which might contain both factors. Despite their dierences, QX-1 and AP1 appear to be related as TRE and QRE cross-compete to an extent.
The position of QRE, downstream of the TATA-box, and its apparent role in the transcription regulation of the BPV-4 promoter are reminiscent of initiator elements (INR) (Novina and Roy, 1996) . INRs have been identi®ed 3' to the TATA box in the so-called composite promoters, found both in cellular and viral genes. INRs bind cellular proteins (IBP), variously belonging, among others, to the TAF, GTF and USF families, whose task is to facilitate the formation of the transcription preinitiation complex and enhance promoter strength (Kaufmann and Smale, 1994) . The general consensus sequence of INRs is PyA(+1)NT/APyPy (Javaheri et al., 1994) and a similar sequence, TAGCTCT, is present at nucleotide 321 ± 327 of the BPV-4 LCR (Figure 2) . The observation that the BPV-4 LCR fails to be stimulated by quercetin when in enhancer configuration (data not shown) supports the hypothesis that quercetin targets a promoter element. The intriguing possibility that the BPV-4 promoter is another example of a composite promoter, and that QX-1 is an IBP regulated by quercetin deserves further study.
Conclusions
The results presented here suggest a likely series of events underpinning the synergism between quercetin and BPV-4 in cell transformation. Quercetin is mutagenic and clastogenic and damaged cells will undergo cell cycle arrest. Expression of the BPV-4 oncogenes, increased by quercetin itself, could cause the cells to overcome the arrest thus allowing proliferation of damaged cells and ®xation of critical mutations. Additional non genetic changes, such as upor down-regulation of kinases as reported in the literature (Graziani et al., 1983; Van Wart-Hood et al., 1989; Matter et al., 1992) and as observed by ourselves (data not shown; Connolly, 1997) , will contribute to cell transformation by altering critical signalling pathways. We have demonstrated that two of the postulated steps following quercetin exposure (growth arrest and up-regulation of the viral LCR) do take place and preliminary results show changes in the tyrosine phosphorylation pattern of several unidenti®ed proteins. Experiments to con®rm escape from cell cycle arrest of PalF cells expressing viral oncoproteins are in progress.
Materials and methods
Cell culture of primary bovine ®broblasts (PalF)
The isolation of ®broblasts from foetal bovine palate was as described previously by Jaggar et al. (1990) . Brie¯y, a small section of palate tissue was taken from a bovine foetus at no more than 5 months gestation. The tissue was immediately placed in a solution of PBS containing antibiotics and incubated overnight at 48C in PBS containing 0.01% EDTA and 0.25% trypsin. The tissue mass was cut into small pieces and placed into a 90 mm dish with Dulbecco's Modi®ed Eagles Medium (DMEM), 10% foetal calf serum. Cells were passaged when approximately 90% con¯uent.
Cell growth analysis
Cells were plated and treated with varying concentrations of quercetin (1 ± 100 mM), or equivalent volumes of ethanol, for dierent lengths of time. Cells from triplicate dishes were counted every second day for each quercetin concentration.
Cell cycle analysis
Fluorescence Activated Cell Sorting (FACS) was used to analyse the cell cycling status of PalF cells, treated with dierent concentration of quercetin (1 ± 100 mM) for dierent periods of time. Cells were harvested and stained with 10 mg/ml propidium iodide in PBS, 0.2% Tween 20. Cell samples were analysed in a Becton Dickinson FACScan Machine and the data processed by the`Cell Quest' software package.
Transient transfection
PalF cells were transiently transfected using the standard protocol for calcium phosphate-mediated transfection. Brie¯y, 2610 5 cells were plated into 60 mm tissue culture dish containing 5 ml of DMEM. The following day a calcium phosphate precipitate containing the DNA was added to the cells and incubated overnight. The following morning the cells were washed twice with PBS and re-fed with fresh medium. After 24 h 20 mM quercetin, or an equivalent volume of ethanol, was added to the medium. Cells were harvested 24 ± 48 h later.
Luciferase reporter assay pGL3 (Promega) is a luciferase reporter vector carrying either the full length LCR of BPV-4 or its mutant derivatives. After transfection, cells were lysed using 16 Reporter Lysis Buer (Promega) and luciferase activity in each sample was assayed using the Luciferase Assay System (Promega) according to the manufacturer's instructions. The amount of luminescence produced was measured in a BioOrbit LKB 1251 Luminometer for 30 s.
b-Galactosidase reporter assay
The plasmid pCH110 (Pharmacia), which contains a functional lacZ gene expressed from the SV40 early promoter, was used in all transient transfections to standardise for eciency of transfection. b-galactosidase activity was measured by changes in light absorbance at 420 nm due to colour changes in the substrate.
Preparation of nuclear extract from cells in culture
PalF cells were treated with quercetin or ethanol, washed twice with ice-cold PBS and removed from the dish with a cell scraper. The cells were pelleted and re-suspended in freshly prepared hypotonic buer (10 mM Tris-HCl pH 7.3, 10 mM KCl, 1.5 mM MgCl 2 , 2 mM PMSF, 4 mM bmercaptoethanol, 0.5 mM benzamidine, 1 mg/ml leupeptin, 1 mg/ml aprotinin). The cells were pelleted again, resuspended in fresh lysis buer (0.4% (v/v) Nonidet P-40, 10 mM Tris-Cl pH 7.3, 10 mM KCl, 1.5 mM MgCl 2 , 2 mM PMSF, 4 mM b-mercaptoethanol, 0.5 mM benzamidine, 1 mg/ml leupeptin, 1 mg/ml aprotinin) and left on ice for 10 min. The nuclei were pelleted and re-suspended in 0.02 M KCl buer (20 mM Tris-Cl pH 7.3, 25% (v/v) glycerol, 1.5 mM MgCl 2 , 0.2 mM EDTA, 20 mM KCl, 2 mM PMSF, 4 mM b-mercaptoethanol, 0.5 mM benzamidine, 1 mg/ml leupeptin, 1 mg/ml aprotinin), followed by the drop-wise addition of 0.6 M KCl buer. The solution was incubated on ice for 30 min then centrifuged at 48C. The supernatant was aliquoted, frozen on dry ice and stored at 7708C.
Electromobility Shift Assay (EMSA)
Samples of nuclear extracts were removed from storage at 7708C and thawed on wet ice. To 5 ml (10 ± 15 mg) of nuclear protein extract, 5 ml 106binding buer (100 mM HEPES pH 7.9, 2 mM EDTA, 1 M NaCl, 1 mg/ml BSA, 40% glycerol), 60 mg/ml polydIdC and 4.4 mM DTT were added followed by 1 ml (*1 ng) of 32 P radioactively labelled double stranded oligonucleotide. Where needed, 100 ng of various unlabelled (cold) double stranded oligonucleotides were added for competition analysis. Each reaction was adjusted to 50 ml with distilled water, mixed and incubated on ice for 30 min. Samples were loaded on a 5% non-denaturing polyacrylamide gel and electrophoresed at 150 v at 48C.
EMSA oligonucleotides
The oligonucleotides used in EMSA were: a 25 bp long fragment from the 3' end of the BPV-4 LCR containing the TRE-like element ( Figure 2) ; the same fragment but with the G at position 317 mutated to a T ( Figure 2) ; a 20 bp long fragment of the collagenase promoter containing the TPA-responsive element (TRE) (Witham et al., 1986) ; and a 21 bp long fragment containing the myc binding element (Blackwood and Eisenman, 1991) .
EMSA supershifts
These assays were performed as described above, but with the addition of antibody to the binding reaction before the addition of radiolabelled oligonucleotide. The antibodies were a pan anti-Fos polyclonal antibody (K-25) from Santa Cruz Biotechnology, Inc; an anti-cJun (730-5) polyclonal antibody from Dr E Black (Beatson Institute, Glasgow), and anti-JunB (725/5) and anti-JunD (783/2) polyclonal antibodies, both from Dr D Gillespie (Beatson Institute, Glasgow).
